Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Geron Corporation    GERN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/05/2016 12/06/2016 12/07/2016 12/08/2016 12/09/2016 Date
2.08(c) 2.12(c) 2.08(c) 2.09(c) 2.08(c) Last
1 477 126 1 056 593 1 350 168 1 263 002 2 013 337 Volume
+3.48% +1.92% -1.89% +0.48% -0.48% Change
More quotes
Financials ($)
Sales 2016 4,56 M
EBIT 2016 -31,1 M
Net income 2016 -32,3 M
Debt 2016 -
Yield 2016 -
Sales 2017 22,4 M
EBIT 2017 -16,3 M
Net income 2017 -20,1 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 72,6x
Capi. / Sales2017 14,8x
Capitalization 331 M
More Financials
Company
Geron Corp. discovers and develops therapeutic products for cancer.It is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.Geron was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park,... 
More about the company
Surperformance© ratings of Geron Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on GERON CORPORATION
12/06 Geron Reports Imetelstat Presentations at American Society of Hematology Annu..
12/01 GERON : Biotech Stocks Under Scanner -- Geron, Keryx Biopharma, Heat Biologics, ..
11/21 GERON CORP : Other Events (form 8-K)
11/07 Geron Announces November Investor Conference Presentation Webcasts
11/04 ASH 2016 : Janssen to Present 43 Abstracts with Data on Ibrutinib, Daratumumab a..
11/03 GERON : reports 3Q loss
11/03 GERON CORP : Results of Operations and Financial Condition, Financial Statements..
11/03 GERON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
11/03 Geron Corporation Reports Third Quarter 2016 Financial Results and Recent Eve..
11/03 Geron Announces Presentations at American Society of Hematology Annual Meetin..
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12/09 BACKTESTING 101, PART 4 : Frictional Costs, To Hedge Or Not To Hedge, And Benchm..
12/08 Should Geron Opt-In?
12/08 What Are The Actionable Takeaways From Geron's ASH Presentations?
11/03 Geron's (GERN) CEO John Scarlett on Q3 2016 Results - Earnings Call Transcrip..
11/03 Geron beats by $0.04, beats on revenue
Advertisement
Chart GERON CORPORATION
Duration : Period :
Geron Corporation Technical Analysis Chart | GERN | US3741631036 | 4-Traders
Full-screen chart
Technical analysis trends GERON CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 4,38 $
Spread / Average Target 110%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John A. Scarlett President, Chief Executive Officer & Director
Hoyoung Huh Chairman
Olivia K. Bloom Chief Financial Officer, Treasurer & Executive VP
Karin Eastham Independent Director
Robert Jay Spiegel Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GERON CORPORATION-56.82%331
AMGEN, INC.-11.63%106 716
GILEAD SCIENCES, INC.-28.16%95 779
CELGENE CORPORATION-5.25%87 962
REGENERON PHARMACEUTIC..-31.32%39 322
ACTELION LTD50.21%22 204
More Results